Valuation
Pharmaceutical PreparationsLive · Yahoo FinancePrice
$78.45
52-Week Range
Decision Context
Scores are balanced across the six engines. No single dimension dominates — this is consistent with a stable, mid-tier quality business.
Based on filing period ending Mar 2026
FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.
Macro Context
Fed Funds Rate
3.64%
Accommodative
10-Year Treasury
4.32%
2026-04-01
Unemployment
4.3%
Near full employment
CPI Index
332.4
2026-04-01
M2 Money Supply
$22.8T
2026-04-01
The Federal Funds rate stands at 3.64% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 4.32%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.3%; Industrial production index is at 102.5; M2 money supply is $22.8T; CPI index stands at 332.4.
SWOT Analysis — PTCT
Inflationary BoomStrengths
Operating Cash Flow: $711.2M (+760.4% YoY) — Operating cash flow grew 760% — the business generated more cash from day-to-day operations.
Net Income: $682.6M (+287.9% YoY) — Profit grew 288% — the company kept more of each dollar earned.
EPS (Diluted): $7.78 (+264.5% YoY) — Earnings per share rose 264% — each share earned more.
Total Assets: $2.9B (+70.0% YoY) — Total assets grew 70% — the company's resource base expanded.
Revenue: $264.7M (+36.2% YoY) — Revenue grew 36% — the company sold more goods or services than the prior year.
Weaknesses
R&D spending is 172% of revenue — heavy investment in future growth, but also a drag on current profitability.
Opportunities
No clear opportunities identified at this time.
Threats
Total liabilities are 107% of total assets — the balance sheet is heavily leveraged with limited equity cushion.
Financial Charts
Year-over-Year Changes
Operating Cash Flow
$711.2M
was -$107.7M
Operating cash flow grew 760% — the business generated more cash from day-to-day operations.
Net Income
$682.6M
was -$363.3M
Profit grew 288% — the company kept more of each dollar earned.
EPS (Diluted)
$7.78
was $-4.73
Earnings per share rose 264% — each share earned more.
Total Assets
$2.9B
was $1.7B
Total assets grew 70% — the company's resource base expanded.
Revenue
$264.7M
was $194.4M
Revenue grew 36% — the company sold more goods or services than the prior year.
Risk Flags
1 high · 0 medium · 1 low- ⚠ High
Total liabilities are 107% of total assets — the balance sheet is heavily leveraged with limited equity cushion.
- ○ Low
R&D spending is 172% of revenue — heavy investment in future growth, but also a drag on current profitability.
Price History
Technical Signals
Daily closes · 1-year dataLatest News
via FinnhubGet the weekly digest
5 company reports + macro context every week, free. No spam.
- Unlimited goal simulations
- 5 free company report summaries per day
- Weekly financial insights newsletter
External Links
Trade PTCT
Links open broker research pages. Not an endorsement or recommendation.
Research PTC Therapeutics, Inc.
Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.